Journal of the American Academy of Dermatology · 2010
Use of warfarin therapy at a target international normalized ratio of 3.0 for cutaneous polyarteritis nodosa.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kawakami Tamihiro, Soma Yoshinao
Аннотация
BACKGROUND: Cutaneous polyarteritis nodosa (CPN) is an uncommon disorder that can be difficult to manage effectively. We have previously suggested that CPN might be associated with the presence of anti-phosphatidylserine-prothrombin complex (anti-PS/PT) antibodies, members of the antiphospholipid antibody family.
OBJECTIVE: To evaluate clinical manifestations and effective treatments of CPN.
METHODS: We conducted a retrospective analysis of three patients with CPN who responded to warfarin therapy. IgG and IgM anti-PS/PT antibodies were measured with a specific enzyme-linked immunosorbent assay.
RESULTS: There was a dramatic improvement in our three CPN patients following warfarin therapy adjusted to a target international normalized ratio (INR) of about 3.0. Active disease progression was halted by sustained warfarin therapy during which the patients experienced resolution of their skin manifestations.
LIMITATIONS: A small number of cases were studied and the study design was retrospective.
CONCLUSION: We propose that warfarin therapy at a target INR of roughly 3.0 could be effective for treating patients with CPN. We further believe that treatment with warfarin led to the effective attenuation of anti-PS/PT antibodies related to prothrombin, and improved the symptoms in our CPN patients.
OBJECTIVE: To evaluate clinical manifestations and effective treatments of CPN.
METHODS: We conducted a retrospective analysis of three patients with CPN who responded to warfarin therapy. IgG and IgM anti-PS/PT antibodies were measured with a specific enzyme-linked immunosorbent assay.
RESULTS: There was a dramatic improvement in our three CPN patients following warfarin therapy adjusted to a target international normalized ratio (INR) of about 3.0. Active disease progression was halted by sustained warfarin therapy during which the patients experienced resolution of their skin manifestations.
LIMITATIONS: A small number of cases were studied and the study design was retrospective.
CONCLUSION: We propose that warfarin therapy at a target INR of roughly 3.0 could be effective for treating patients with CPN. We further believe that treatment with warfarin led to the effective attenuation of anti-PS/PT antibodies related to prothrombin, and improved the symptoms in our CPN patients.
Предметные рубрики MeSH
AdultAnticoagulantsBiopsy, NeedleDose-Response Relationship, DrugDrug Administration ScheduleEnzyme-Linked Immunosorbent AssayFemaleFollow-Up StudiesHumansImmunohistochemistryInternational Normalized RatioLeg UlcerMiddle AgedPolyarteritis NodosaProthrombinRetrospective StudiesSampling StudiesSeverity of Illness IndexTreatment OutcomeWarfarinWound HealingYoung Adult